SEMA-RENAL: Real-World Effects of Subcutaneous Semaglutide on Kidney Outcomes
In a real-world cohort of patients with type 2 diabetes, subcutaneous semaglutide was associated with sustained reductions in albuminuria and stable kidney function over 12 months, supporting its role as a beneficial adjunct in managing chronic kidney disease.